Based on these published data and the results presented thus far; we hypothesized that SAC-targeting drugs activate CASP-2 in tumor cells and ultimately trigger CASP-3 mediated apoptosis or aneuploidy/polyploidy and survival, the balance between the two outcomes being determined by BID levels (Fig. 7A). This evidence concerns the gene CASP2 and neoplasm.